Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

Dabrafenib plus trametinib has demonstrated clinical benefit across multiple BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma, non –small-cell lung cancer (NSCLC) and anaplastic thyroid cancer. Pyrexia is a common adverse event in patients treated with dabrafenib plus trametinib. Here, we characterise the incidence, patterns and management of pyrexia in patients receiving dabrafenib plus trametinib in clinical trials.

Source: European Journal of Cancer - July 2, 2021 Category: Cancer & Oncology Authors: Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Keith T. Flaherty, Hussein A. Tawbi, Alexander M. Menzies, Hiya Banerjee, Mike Lau, Georgina V. Long Tags: Original Research Source Type: research